Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Endostatin and Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer diagnosis and fine needle aspiration for lymph node metastasis diagnosis)~* Stage ⅡA-ⅢC~* Age 18-70~* ECOG performance status 0-2~* No evidence of distant metastasis~* No previous therapy~* Normal hematologic function~* left ventricular ejection fraction greater than 50 percent~* No abnormality of renal or liver function~* Written informed consent~Exclusion Criteria:~* With allergic constitution or possible allergic reflection to drugs to be used in this study~* Any concurrent uncontrolled medical or psychiatric disorder~* History of severe heart diseases, including congestive heart failure, unstable angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or heart valve disease.~* History of bleeding diathesis~* Being pregnant or nursing

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: ACTIVE_COMPARATOR): neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
- chemotherapy plus endostatin (Type: EXPERIMENTAL): neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin

Based on this trial design, predict the completion outcome and termination type (if applicable).